Table 4.

Summary of all‐causality AEs (SAS)

	Tofacitinib 5 mg b.i.d., n (%)	Tofacitinib 10 mg b.i.d., n (%)
Median duration of exposure, days (range)	365 (139–372)	365 (7–370)

Week 0–16	n = 47	n = 47
AEs	27 (57.4)	28 (59.6)
Serious AEs	0	1 (2.1)
Discontinuations due to AEs	0	1 (2.1)
Most common AEs (≥5% of patients in any group)
Nasopharyngitis	9 (19.1)	8 (17.0)
Headache	1 (2.1)	3 (6.4)
Influenza	3 (6.4)	0
Decreased hemoglobin	0	3 (6.4)

Weeks 0–52†	Total n = 94
AEs	78 (83.0)
Serious AEs	4 (4.3)
Discontinuations due to AEs	8 (8.5)
Most common AEs (≥5% of patients)
Nasopharyngitis	28 (29.8)
Herpes zoster (serious and non‐serious)	16 (17.0)‡
Psoriasis	9 (9.6)
Tinea pedis	9 (9.6)
Influenza	6 (6.4)
Increased blood creatine phosphokinase	5 (5.3)
Decreased hemoglobin	5 (5.3)

^†AEs occurring up to day 372 are included. ^‡Three cases were serious. AEs, adverse events; SAS, safety analysis set.